November 24, 2015
1 min read

Omalizumab reduces exacerbation rate in children with asthma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Adding omalizumab to guide-line based care prior to the start of the school year reduced fall asthma exacerbation rates among inner-city children and adolescents, according to results of a multicenter clinical trial.

“Our study shows that an effective, preventative strategy for fall exacerbations can be achieved with targeted, seasonal treatment using omalizumab, suggesting a paradigm shift for managing high-risk patients,” Stephen J. Teach, MD, MPH, of Children’s National Health System in Washington, D.C., said in a press release.

Teach and colleagues conducted a double blind, double placebo-controlled study of 478 children with asthma aged 6 to 17 years old who lived in the inner city. Study participants — all of whom had a recent asthma exacerbation — were randomly assigned to omalizumab (Xolair; Genentech, Novartis), placebo or an inhaled corticosteroid boost.

Researchers found 11.3% of participants in the omalizumab group had exacerbations compared with 21% of patients in the placebo group (OR = 0.48; 95% CI, 0.25-0.92). However, there was no significant difference between the omalizumab and inhaled corticosteroid groups (OR = 0.73; 95% CI, 0.33-1.64).

Among study participants with an exacerbation during the 4-month to 9-month run-in phase of the trial, omalizumab was significantly more effective than placebo (6.4% vs. 36.3%; OR = 0.12; 95% CI, 0.02-0.64) or inhaled corticosteroid boost (2% vs 27.8%; OR = 0.05; 95% CI, 0-0.98), results of a prespecified subgroup analysis showed.

Rates of adverse events were comparable between study arms, researchers wrote. – by Jeff Craven

Disclosure: Teach reports grants from Novartis, PCORI, the Fight for Children Foundation, the Stewart Foundation, EJF Philanthropies, the NIH/National Institute of Allergy and Infectious Diseases and the NIH/National Heart, Lung, and Blood Institute. Please see the full study for a list of all other researchers’ relevant financial disclosures.